SEC Form 4 · accession 0001179110-16-031625
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maria Teresa Hilado
Officer — Chief Financial Officer
Period of report
Nov 11, 2016
Accepted (ET)
Nov 15, 2016 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001 | Nov 11, 2016 | P | 702 | $213.31 | A | 12,659 | D | |
| Ordinary Shares, par value $0.0001F1,F2 | Nov 11, 2016 | P | 720 | $208.0453 | A | 13,379 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $208.00 to 208.06, inclusive. The reporting person undertakes to provide Allergan plc, any security holder of Allergan plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in footnote (1) of this Form 4.
- F2Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.